ESR1 and breast carcinoma: In the case of MGERA, we chose estrogen receptor, ESR1, as the initial starting point, since it is one of the dominant and systemic factor in breast cancer; in the case of TraceRNA, we also chose gene ESR1 and its modulated gene network.